Hair loss affects up to 52% of postmenopausal women, making it one of the most prevalent physical changes of the menopausal transition.[1] Despite this, it rarely gets discussed alongside hot flashes or sleep disruption. Many women notice gradual diffuse thinning, a wider parting, or increased shedding at the brush, without connecting it to the same hormonal shift driving their other symptoms.

Understanding the mechanism clarifies why this type of hair loss looks and behaves differently from the acute shedding that follows illness or stress, and why treatment requires a different approach.

The Hormonal Mechanism

Hair follicles are estrogen-sensitive tissue. Throughout reproductive life, estrogen prolongs the anagen (growth) phase of the hair cycle and supports the thickness and pigmentation of each hair shaft.[2] When estrogen declines at menopause, this supportive effect is withdrawn.

The pattern that results is driven by the relative rise in androgen activity. As estrogen falls, testosterone and its more potent metabolite dihydrotestosterone (DHT, converted by the enzyme 5α-reductase) are no longer counterbalanced. DHT binds to androgen receptors in scalp follicles and triggers follicular miniaturisation: the progressive conversion of thick terminal hairs into fine, short vellus hairs.[2] This is the same process that drives male androgenetic alopecia, but in women it tends to produce diffuse thinning across the crown and widening of the parting rather than a receding hairline or complete baldness.

Oxidative stress and low-grade inflammation, both of which increase after estrogen withdrawal, compound this process by impairing scalp microcirculation and nutrient delivery to follicles.[1] The combined result is slower growth, finer individual hairs, reduced density, and sometimes altered texture.

Rule Out Thyroid and Iron First

Thyroid disorders and iron deficiency are both common in perimenopausal women and both cause hair loss that is clinically indistinguishable from androgenetic alopecia. Before assuming the cause is hormonal, a blood test covering TSH, ferritin, and a full blood count is warranted.

Iron deficiency is easy to overlook during perimenopause: heavier, more irregular periods increase blood loss, yet the symptom gets attributed to menopause rather than prompting investigation of iron stores. Ferritin below 30–50 mcg/L can contribute to hair loss even when haemoglobin is normal. Correcting iron deficiency frequently produces noticeable hair improvement within several months.

Hypothyroidism, even subclinical, disrupts the hair cycle and causes diffuse thinning. Its symptoms (fatigue, weight changes, cold intolerance, brain fog) overlap extensively with perimenopausal symptoms, making it easy to miss without testing.

What Helps

Minoxidil (topical). Minoxidil is the best-evidenced topical treatment for female pattern hair loss. It works by prolonging the anagen phase and stimulating follicular activity. The 2% and 5% topical solutions are both licensed for women; the 5% concentration produces greater hair count improvements in trials, though scalp irritation is more common. Minoxidil requires sustained use: improvements emerge over 3–6 months and reverse on stopping.[3] It does not address the androgenetic mechanism and works best as maintenance therapy once existing hair has been preserved.

HRT. For women who have other reasons to consider systemic HRT, restoring estrogen levels can slow the androgenetic process by re-establishing androgen-estrogen balance. A pilot study in Japanese postmenopausal women found that estradiol replacement produced measurable improvements in hair shaft diameter and growth rate.[4] The evidence for HRT specifically for hair outcomes is limited in scale, but the biological mechanism is sound, and women on HRT frequently report hair improvement as a secondary benefit.

Spironolactone (off-label). Spironolactone is an aldosterone antagonist that also blocks androgen receptors and inhibits 5α-reductase, reducing DHT's effect on scalp follicles. It is used off-label for female pattern hair loss at doses of 50–200 mg/day and has reasonable evidence from observational studies and small trials. Contraindicated in pregnancy; requires blood pressure and electrolyte monitoring.

Broader anti-androgen options, including flutamide and finasteride off-label in postmenopausal women, have evidence in small trials. These should be discussed with a dermatologist.

When to See a GP or Dermatologist

Hair loss warrants medical assessment if:

  • It is sudden or rapid: large-scale shedding over weeks, not gradual thinning over months
  • It is patchy rather than diffuse (circular bald patches suggest alopecia areata, an autoimmune condition needing separate treatment)
  • It involves scalp symptoms: burning, itching, or scaling (scarring alopecias cause permanent follicle destruction if untreated)
  • Thyroid function (TSH) and iron stores (ferritin) have not been tested; both are common, treatable causes
  • Significant thinning has not responded to six months of consistent minoxidil use

A GP can arrange the initial blood screen and refer to dermatology if needed. Dermatologists can perform scalp dermoscopy and biopsy to distinguish androgenetic alopecia (diffuse, manageable) from scarring alopecias (patchy, inflammatory, requiring urgent treatment to prevent permanent loss).

Treatments Without Reliable Evidence

Despite widespread marketing, evidence for biotin supplementation in women without biotin deficiency is negligible. Most women with adequate diets are not biotin-deficient, and supplementing excess biotin does not stimulate hair growth. High-dose biotin can also interfere with thyroid and other blood test results, which is a practical problem when investigating hair loss.

Supplement formulations marketed for hair growth (typically combining biotin, collagen peptides, and various vitamins) lack RCT evidence in menopausal women. Some individual ingredients have plausible mechanistic support (adequate zinc, iron, and protein are necessary for normal hair growth), but the products themselves have not been tested against the clinical question.

References

[1] Panza, G., et al. (2025). Menopause and hair loss in women: Exploring the hormonal transition. Journal of Cosmetic Dermatology. https://pubmed.ncbi.nlm.nih.gov/40318238/

[2] Marks, D. H., Mirmirani, P. (2024). Menopause, skin and common dermatoses. Part 1: hair disorders. Clinical and Experimental Dermatology. https://pmc.ncbi.nlm.nih.gov/articles/PMC10092469/

[3] Olsen, E. A., Dunlap, F. E., Funicella, T., et al. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology, 47(3), 377-385. https://doi.org/10.1067/mjd.2002.124088

[4] Nakamura, M., et al. (2024). Clinical and phototrichogrammatic evaluation of estradiol replacement therapy on hair growth in postmenopausal Japanese women with female pattern hair loss. Journal of Cosmetic Dermatology, 22(12). https://pmc.ncbi.nlm.nih.gov/articles/PMC10615536/